Literature DB >> 6193665

Prevention of dextran-induced anaphylactic reactions by hapten inhibition. I. A Scandinavian multicenter study on the effects of 10 ml dextran 1, 15% administered before dextran 70 or dextran 40.

K G Ljungström, H Renck, H Hedin, W Richter, B Rosberg.   

Abstract

In an open prospective study the prevention of dextran-induced anaphylactic reactions (DIAR) by hapten inhibition was investigated in 29 252 patients. Forty-nine hospitals in Sweden, Norway and Finland participated in the study which was running for two years. Ten ml of dextran 1, 15%, (Promiten, Pharmacia AB, Uppsala, Sweden) with a weight average molecular weight of 1 000 dalton was injected intravenously two minutes before infusion of dextran 70 (Macrodex) or dextran 40 (Rheomacrodex). DIAR were graded according to severity from I to V. Six grade III and one grade IV reactions occurred, representing an incidence of severe DIAR of 0.024%. Compared to a large historical control material, preinjection of 10 ml of dextran 1 exerts a partially protective effect, but no statistical proof can be given. Consequently trials have been started with a 20 ml dose of dextran 1. Adverse reactions to the preinjection of 10 ml of dextran 1 were observed in 0.072%. These reactions were of a mild and shortlasting nature and considered to be of minor clinical importance.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6193665

Source DB:  PubMed          Journal:  Acta Chir Scand        ISSN: 0001-5482


  5 in total

1.  Cardiac arrest after intrauterine instillation of 32% dextran-70 during hysteroscopy.

Authors:  P J Kuzma; T M McLoughlin; R J Engler
Journal:  Can J Anaesth       Date:  1995-06       Impact factor: 5.063

Review 2.  Desensitisation today.

Authors:  N Eiser
Journal:  BMJ       Date:  1990-06-02

Review 3.  Current status of allergen immunotherapy (hyposensitization): memorandum from a WHO/IUIS meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

Review 4.  The use of plasma substitutes with special attention to their side effects.

Authors:  K F Messmer
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

5.  Dextran prophylaxis of fatal pulmonary embolism.

Authors:  K G Ljungström
Journal:  World J Surg       Date:  1983-11       Impact factor: 3.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.